MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413988 | Name: Ecabet Free Base
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ecabet Free Base is a prescription eye drop for the treatment of dry eye syndrome. Ecabet represents a new class of molecules that increases the quantity and quality of mucin produced by conjunctival goblet cells and corneal epithelia. Mucin is a glycoprotein component of tear film that lubricates while retarding moisture loss from tear evaporation. Ecabet is currently marketed in Japan as an oral agent for treatment of gastric ulcers and gastritis.

Chemical Structure

Ecabet Free Base
Ecabet Free Base
CAS#33159-27-2 (free base)

Theoretical Analysis

MedKoo Cat#: 413988

Name: Ecabet Free Base

CAS#: 33159-27-2 (free base)

Chemical Formula: C20H28O5S

Exact Mass: 380.1657

Molecular Weight: 380.49

Elemental Analysis: C, 63.13; H, 7.42; O, 21.02; S, 8.43

Price and Availability

Size Price Availability Quantity
100mg USD 285.00 2 Weeks
250mg USD 500.00 2 Weeks
1g USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
33159-27-2 (free base) 86408-72-2 (sodium) 219773-47-4 (sodium hydrate) 219773-47-4 (sodium pentahydrate)
Synonym
Ecabet Free Base; Ecabetum
IUPAC/Chemical Name
13-Isopropyl-12-sulfopodocarpa-8,11,13-trien-15-oic acid
InChi Key
IWCWQNVIUXZOMJ-RLLQIKCJSA-N
InChi Code
InChI=1S/C20H28O5S/c1-12(2)14-10-13-6-7-17-19(3,8-5-9-20(17,4)18(21)22)15(13)11-16(14)26(23,24)25/h10-12,17H,5-9H2,1-4H3,(H,21,22)(H,23,24,25)/t17-,19-,20+/m1/s1
SMILES Code
C[C@]1(C(O)=O)CCC[C@]2(C)C3=C(C=C(C(C)C)C(S(=O)(O)=O)=C3)CC[C@@]12[H]
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 380.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wang Y, Wang B, Lv ZF, Yang Y, Wang F, Wang H, Chen S, Xie Y, Zhou X. Efficacy and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Helicobacter. 2014 Oct;19(5):372-81. doi: 10.1111/hel.12136. Epub 2014 May 14. PMID: 24826809. 2: Takahashi S, Tanaka A. [Ecabet sodium]. Nihon Rinsho. 2002 Feb;60 Suppl 2:711-6. Japanese. PMID: 11979876. 3: Ito Y, Shibata K, Hongo A, Kinoshita M. Ecabet sodium, a locally acting antiulcer drug, inhibits urease activity of Helicobacter pylori. Eur J Pharmacol. 1998 Mar 19;345(2):193-8. doi: 10.1016/s0014-2999(97)01622-1. PMID: 9600637. 4: Lawrance IC. Ecabet sodium: a potential new agent in the management of distal colitis. J Gastroenterol Hepatol. 2010 Jul;25(7):1182-4. doi: 10.1111/j.1440-1746.2010.06339.x. PMID: 20594242. 5: Kusumoto K, Kawahara T, Kuwano Y, Teshima-Kondo S, Morita K, Kishi K, Rokutan K. Ecabet sodium inhibits Helicobacter pylori lipopolysaccharide-induced activation of NADPH oxidase 1 or apoptosis of guinea pig gastric mucosal cells. Am J Physiol Gastrointest Liver Physiol. 2005 Feb;288(2):G300-7. doi: 10.1152/ajpgi.00274.2004. Epub 2004 Sep 30. PMID: 15458921. 6: Kinoshita M, Endo M, Yasoshima A, Saito N, Yamasaki K, Chishima S, Narita H. Ecabet sodium, a novel locally-acting anti-ulcer agent, protects the integrity of the gastric mucosal gel layer from pepsin-induced disruption in the rat. Aliment Pharmacol Ther. 1999 May;13(5):687-94. doi: 10.1046/j.1365-2036.1999.00502.x. PMID: 10233194. 7: Okuyama K, Saito N, Kume E, Noto T, Nagasaki M. Ecabet sodium prevents esophageal lesions induced by the reflux of gastric juice in rats. Inflammopharmacology. 2007 Apr;15(2):90-4. doi: 10.1007/s10787-006-1538-0. PMID: 17450449. 8: Kim JY, Kim DH, Min KA, Maeng HJ, Jang DJ, Cho KH. Preparation, Characterization, and In Vitro Release of Chitosan-Ecabet Electrolyte Complex for the Mucosal Delivery. J Nanosci Nanotechnol. 2019 Feb 1;19(2):640-645. doi: 10.1166/jnn.2019.15961. PMID: 30360135. 9: Rah YC, Choi J, Yoo MH, Yum G, Park S, Oh KH, Lee SH, Kwon SY, Cho SH, Kim S, Park HC. Ecabet sodium alleviates neomycin-induced hair cell damage. Free Radic Biol Med. 2015 Dec;89:1176-83. doi: 10.1016/j.freeradbiomed.2015.11.007. Epub 2015 Nov 10. PMID: 26561773. 10: Katagiri F, Inoue S, Sato Y, Itoh H, Takeyama M. Ecabet sodium raises plasma levels of calcitonin generelated peptide and substance P in healthy humans. J Pharm Pharmacol. 2005 Jun;57(6):799-805. doi: 10.1211/0022357056271. PMID: 15969937. 11: Shimoyama T, Fukuda S, Liu Q, Nakaji S, Munakata A, Sugawara K. Ecabet sodium inhibits the ability of Helicobacter pylori to induce neutrophil production of reactive oxygen species and interleukin-8. J Gastroenterol. 2001 Mar;36(3):153-7. doi: 10.1007/s005350170122. PMID: 11291877. 12: Kagaya H, Kato M, Asaka M. [Ecabet sodium (ECA) + PPI + AMPC therapy for clarithromycin-resistant Helicobacter pylori infections]. Nihon Rinsho. 2002 Feb;60 Suppl 2:455-9. Japanese. PMID: 11979827. 13: Munakata W, Liu Q, Shimoyama T, Sawaya M, Umeda T, Sugawara K. Ecabet sodium attenuates reactive oxygen species produced by neutrophils after priming with bacterial lipopolysaccharides. Luminescence. 2003 Nov-Dec;18(6):330-3. doi: 10.1002/bio.745. PMID: 14694422. 14: Ito Y, Hongo A, Kinoshita M, Tamaki H. Mechanism of anti-urease action by the anti-ulcer drug ecabet sodium. Biol Pharm Bull. 1995 Jun;18(6):850-3. doi: 10.1248/bpb.18.850. PMID: 7550119. 15: Liang J, Li J, Han Y, Xia J, Yang Y, Li W, Zhang S, Wu Y, Yuan Y, Li Z, Du Y, Chen M, Chen B, Jiang B, Bai Y, Wen Q, Wu K, Fan D. Helicobacter pylori eradication with ecabet sodium, omeprazole, amoxicillin, and clarithromycin versus bismuth, omeprazole, amoxicillin, and clarithromycin quadruple therapy: a randomized, open-label, phase IV trial. Helicobacter. 2012 Dec;17(6):458-65. doi: 10.1111/j.1523-5378.2012.00971.x. Epub 2012 Jul 2. PMID: 23066868. 16: Kawakami K, Yasuda M, Ishii K, Kokusenya Y, Sato T. A kinetic study of protein binding to ecabet sodium using quartz-crystal microbalance. Chem Pharm Bull (Tokyo). 1999 Jul;47(7):919-22. doi: 10.1248/cpb.47.919. PMID: 10434394. 17: Shimoyama T, Fukuda Y, Fukuda S, Munakata A, Yoshida Y, Shimoyama T. Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients. J Gastroenterol. 1996 Nov;31 Suppl 9:59-62. PMID: 8959522. 18: Hayashi S, Sugiyama T, Yokota K, Isogai H, Isogai E, Shimomura H, Oguma K, Asaka M, Hirai Y. Combined effect of rebamipide and ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cells. Microbiol Immunol. 2000;44(7):557-62. doi: 10.1111/j.1348-0421.2000.tb02534.x. PMID: 10981828. 19: Kim J, Kim K, Lee JS, Kim SY, Kim KO, Kim YJ, Kwon KA, Park DK, Chung JW. [The Efficacy of Rebamipide or Ecabet Sodium Supplementation for Helicobacter pylori Eradication Therapy Compared with Quadruple (Concomitant) Regimen]. Korean J Gastroenterol. 2018 Apr 25;71(4):204-212. Korean. doi: 10.4166/kjg.2018.71.4.204. PMID: 29684969. 20: Ito Y, Onoda Y, Nakamura S, Tagawa K, Fukushima T, Sugawara Y, Takaiti O. Effects of the new anti-ulcer drug ecabet sodium (TA-2711) on pepsin activity. II. Interaction with substrate protein. Jpn J Pharmacol. 1993 Jun;62(2):175-81. doi: 10.1254/jjp.62.175. PMID: 8371516.

View History

Ecalcidene

Ecalcidene